SSSW(SH:688399) Mei Ri Jing Ji Xin Wen·2025-08-27 15:56Core Viewpoint - The management team of Shuoshi Biotechnology (SH688399) voluntarily decided to reduce their salaries to support the company's operational cost optimization and enhance management efficiency in response to the challenging global economic environment and industry conditions [1][3]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2]. - Other executives, including Liu Zhonghua and Hu Tongyuan, will see a 40% salary reduction, while the financial director, Meng Yuanyuan, and employee supervisors will have reductions of 10% and 5%, respectively [2]. Company Performance and Financials - In 2023, Shuoshi Biotechnology reported a significant loss, with a net profit of -374 million yuan, a decrease of 120.45% year-on-year [6]. - The company's revenue for the first half of 2025 was 176 million yuan, down 1.05% year-on-year, with a net profit of 3.99 million yuan, reflecting an 86.35% decline compared to the previous year [6]. - The decline in profitability is attributed to price pressures from national procurement in the in vitro diagnostics industry and changes in tax rates affecting gross margins [6]. Cost Management and Operational Efficiency - The company is committed to ongoing cost reduction and efficiency improvement measures, alongside expanding market reach to enhance operational efficiency and competitiveness [3]. - Sales, management, and R&D expenses have all decreased, with sales expenses at 64.25 million yuan (down 1.94%), management expenses at 31.68 million yuan (down 21.02%), and R&D expenses at 40.64 million yuan (down 13.11%) [6]. R&D Investment - R&D investment accounted for 23.15% of the company's revenue, which is a decrease of 3.21 percentage points year-on-year [7].